(MOPETT) Trial

More documents

Recommendations

Info

Rationale for Efficacy of “ Safe dose” thrombolysis • Thromboembolus in pulmonary arterial circulation is exquisitely sensitive to lysis • Lungs= point of convergence of venous circulation • Pulmonary blood flow= Entire CO • Almost all t-PA molecules converge in lungs • Different than in thromboembolic CVA and acute MI • Brain 15% of CO; Heart 5%; hence same dose should not necessarily apply
Page 1 and 2: Moderate Pulmonary Embolism Treated
Page 3 and 4: Pulmonary Embolism • >100,000 ann
Page 5 and 6: • Standard dose t-PA 100mg in 2 h
Page 7: “ SAFER DOSE t-PA”
Page 18 and 19: Primary Endpoints 1) Pulmonary HTN
Page 20 and 21: Inclusion criteria • PE + 2 of th
Page 22 and 23: Exclusion Criteria • BP≥200/100
Page 24 and 25: FG CG p Value n= 61 N=60 Male 28 (4
Page 28 and 29: Intense fluctuations in PTT with
Page 30 and 31: • 66% had BNP or Trop I elevation
Page 32 and 33: Primary Endpoints Pulmonary HTN at
Page 34 and 35: Thrombolysis serving as a “pulmon
Page 37 and 38: Conclusions • Low dose thrombolys

(MOPETT) Trial

Create successful ePaper yourself

Delete template?

Save as template?